D&D Pharmatech Inc. (KOSDAQ:347850)

South Korea flag South Korea · Delayed Price · Currency is KRW
92,400
+3,600 (4.05%)
At close: Feb 27, 2026
637.72%
Market Cap 4.02T
Revenue (ttm) 8.36B
Net Income (ttm) -34.76B
Shares Out 43.54M
EPS (ttm) -845.57
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 825,776
Average Volume 724,983
Open 89,200
Previous Close 88,800
Day's Range 88,900 - 94,300
52-Week Range 10,125 - 113,700
Beta n/a
RSI 55.20
Earnings Date Mar 20, 2026

About D&D Pharmatech

D&D Pharmatech Inc. engages in the research and development and manufacturing of pharmaceuticals in South Korea. It develops oral peptides, such as MET-002o, MET-224o, MET-097o, DD03, DD07, and DD14 programs for obesity indications in the development phase; injectable peptides, including DD01 for MASH indications; NLY12 and DD15 for obesity indications; and Pegsebrenatide (NLY01) for Parkinson’s and Alzheimer’s diseases. The company is also involved in the development of TLY012, an injectable protein for systemic sclerosis, liver fibrosis, and ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 347850
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.